MySmarTrend
← Insider Monitor
Pharvaris N.V. logo
PHVS

Pharvaris N.V.

Nasdaq · Pharmaceutical Preparations

2
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Pharvaris N.V. is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists, including deucrictibant, for the treatment of hereditary angioedema and other bradykinin-mediated conditions.

Industry
Pharmaceutical Preparations
Headquarters
Leiden
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Lu PengPresidentSell$610KSep 8, 2026
Modig BerndtChief Executive OfficerSell$80KAug 14, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for PHVS.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable PHVS activity by email

Free alerts for the insider and congressional trades worth watching.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.